Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies is well positioned because clonoSEQ is the only FDA-cleared MRD assay named in updated NCCN multiple myeloma guidelines, which should expand test timepoints and push utilization above the current ~2.3 to 2.5 tests per patient toward at least 3.5 over time. The company is already showing strong operating momentum, with Q2'26 MRD volumes up 43% Y/Y, MRD revenue up 33% ex-milestones, and ASPs rising to $1,382 per test, while 2026 MRD revenue guidance was raised to $268M-$278M and gross margins reached 71%. Management’s plan to separate the core MRD business from Immune Medicine, supported by a $357M cash balance at the end of Q2'26 and a $300M convertible offering, could unlock value by allowing the profitable diagnostics franchise to be valued on its own merits.

Adaptive Biotechnologies is facing a highly uncertain separation of its Immune Medicine business from its core MRD operations by YE'26, and there is no guarantee the transaction will happen on that timeline, at all, or on favorable terms. Its investment case also depends heavily on continued record growth in the MRD unit, so any quarter that fails to set a new high or meet expectations could quickly pressure sentiment and the stock. Meanwhile, the company trades at a significant premium multiple while confronting adoption, reimbursement, clinical guideline, and competition risks, leaving limited margin for error.